Phase II evaluation of piperazinedione in metastatic breast carcinoma
Palmer, R.L.; Samal, B.A.; Vaughn, C.B.; Tranum, B.L.
Cancer Treatment Reports 61(9): 1711-1712
1977
ISSN/ISBN: 0361-5960 PMID: 340035 Document Number: 110392
Piperazinedione was well tolerated by all patients except for nausea and vomiting and myelosuppression. Myelosuppression was significant, especially thrombocytopenia which frequently required delay in treatment or a dose reduction. The toxicity found in this study was similar to that observed in the phase I study. Seventy percent of the patients had osseous metastases and this factor coupled with major prior polychemotherapy exposure may have played a significant role in predisposing these patients to myelosuppression. The recommended starting dose for patients with advanced malignancy who underwent extensive prior chemotherapy is 9 mg/m2 every 3 wk. Patients with less extensive prior treatment may tolerate a dose of 12 mg/m2. No appreciable antitumor effect was found in this group of patients. The 3 pateints with soft tissue metastases who had a partial response exacerbated within 10 wk. One was treated with 12 mg/m2 of piperazinedione while the other 2 were treated with 9 mg/m2.